Multiplikator Forward P/S: iCAD Corp (ICAD)
The forward P/S chart for iCAD, Inc. (ICAD) demonstrates the resilience of an asset shielded from macroeconomic volatility by stable demand for medtech. Growth is driven by the expansion of B2B subscriptions for AI software in radiology centers and partnerships with equipment behemoths. The mass adoption of early breast cancer detection systems is stimulating revenue. The value of 5.50 determines the current status of the sales valuation parameter.
Rincian analitis perusahaan iCAD, Inc.
- rega saiki lan proyeksi nilai saham:
- indikator kapitalisasi bursa perusahaan:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal iCAD, Inc.|ICAD - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas iCAD|ICAD - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku iCAD, Inc.|ICAD - Kewajiban jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan iCAD|Rasio cepet icadmed.com
- rincian asil keuangan lan kelipatan valuasi:
ICAD - Asil keuangan resik|Proyeksi bathi mangsa ngarep iCAD, Inc.|ICAD - Koefisien rega marang bathi|Pangali Forward P/E iCAD|ICAD - Pangali PEG|Pangali EV/EBITDA iCAD, Inc.|ICAD - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) iCAD|ICAD - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan icadmed.com|ICAD - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep iCAD, Inc.
- indikator dodolan lan pendapatan:
Pambiji fundamental perusahaan:iCAD Corp ICAD
Patents and FDA approval for AI-driven breast cancer diagnostics create high barriers to entry for competitors, which is reflected in the forward P/S ratio of 5.50 for iCAD, Inc. (ICAD). This indicator is calculated as the ratio of market capitalization to projected revenue, allowing investors to assess the extent to which future sales expectations are priced in and determine the asset's degree of overboughtness.
Pesaing iCAD, Inc. (ICAD)
Multiplikator Forward P/S ONC (BeiGene)|HALO - Multiplikator forward rega marang pendapatan|RevMed - Multiplikator Forward P/S|AAPG - Multiplikator Forward P/S|CGON: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan URGN|Multiplikator forward rega marang pendapatan BCAX|PSNL: Rega forward marang dodolan|Multiplikator Forward P/S ERAS|Rasio kapitalisasi marang dodolan sing dikarepake Delcath Corp|Rasio rega marang prakiraan pendapatan Y-mAbs Therapeutics YMAB|AURA: Kapitalisasi marang prakiraan pendapatan|Candel - Multiplikator Forward P/S|Accuray Inc (ARAY) - Multiplikator forward rega marang pendapatan|SLS (sellaslifesciences.com) - Multiplikator forward rega marang pendapatan|ACTU - Rasio kapitalisasi marang dodolan sing dikarepake|CTOR (Citius Oncology, Inc.) - Multiplikator Forward P/S|TuHURA (HURA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S TARA|Multiplikator forward rega marang pendapatan Fate Therapeutics Inc FATE|Multiplikator Forward P/S WHWK (Aadi Bioscience)|Multiplikator Forward P/S TScan Therapeutics Inc TCRX|Champions Oncology Corp - Multiplikator Forward P/S|XBIT (XBiotech Inc.) - Kapitalisasi marang prakiraan pendapatan|CVM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan OS Therapies Inc.|RADX (Radiopharm Theranostics Limited) - Multiplikator Forward P/S|Multiplikator Forward P/S Artiva|Rasio rega marang prakiraan pendapatan Adlai Nortye Ltd. (ANL)|verupharma.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S TPST (Tempest Therapeutics, Inc.)|XLO - Multiplikator forward rega marang pendapatan|Enochian BioSciences - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Mural Oncology plc|kairospharma.com (KAPA) - Rasio rega marang prakiraan pendapatan|OnKure Therapeutics - Rega forward marang dodolan|Multiplikator forward rega marang pendapatan GDTC|CRIS: Rega forward marang dodolan|Multiplikator Forward P/S APLM|Multiplikator forward rega marang pendapatan Tharimmune Corporation THAR|Advanced Biomed - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S genprex.com GNPX|CLDI - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan SBFM (Sunshine Biopharma Inc.)|XBIO: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Salarius Pharma (SLRX)|PPBT (Purple Biotech) - Multiplikator Forward P/S|AON (AONC) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S BGNE|Multiplikator forward rega marang pendapatan Checkpoint Therapeutics Inc. CKPT|Multiplikator Forward P/S ELEV (Elevation Oncology, Inc.)|Multiplikator Forward P/S Ikena Oncology Inc. IKNA|Notable Labs, Ltd. - Multiplikator Forward P/S|VIRX (Viracta Therapeutics) - Kapitalisasi marang prakiraan pendapatan|MOR (MorphoSys) - Multiplikator forward rega marang pendapatan|NAYA Biosciences Inc - Rega forward marang dodolan|AAPGV (Ascentage Pharma Group Ltd) - Multiplikator Forward P/S
